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Acetaminophen is a widespread and commonly used painkiller all over the world. However, it can cause
liver damage when taken in large doses or at repeated chronic doses. Current models of acetaminophen
metabolism are complex, and limited to numerical investigation though provide results that represent
clinical investigation well. We derive a mathematical model based on mass action laws aimed at cap-
turing the main dynamics of acetaminophen metabolism, in particular the contrast between normal and
overdose cases, whilst remaining simple enough for detailed mathematical analysis that can identify key
parameters and quantify their role in liver toxicity. We use singular perturbation analysis to separate the
different timescales describing the sequence of events in acetaminophen metabolism, systematically
identifying which parameters dominate during each of the successive stages. Using this approach we
determined, in terms of the model parameters, the critical dose between safe and overdose cases,
timescales for exhaustion and regeneration of important cofactors for acetaminophen metabolism and
total toxin accumulation as a fraction of initial dose.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Acetaminophen (paracetamol; APAPN-acetyl p-aminophenol) is
a commonly used pain killer and antipyretic. It is an easy to obtain
medication that is nowadays widely stocked in pharmacies and
corner shops, in packets of up to 32 tablets (16 in Europe); enoughr Ltd. This is an open access article
hoff).to cause serious liver damage if ingested in a single dose. It is
estimated that in the U.S. an average of 56,000 people are
admitted to the hospital each year due to acetaminophen over-
doses and their related effects. Over 450 people a year go on to die
from acetaminophen overdose. In the U.S. alone, adverse drug
reactions are ranked as being between the 4th and 6th leading
cause of death (Lazarou et al., 1998). Worryingly, around a quarter
of these deaths are not from an intentional overdose by way of a
suicide attempt, but from chronic use of the drug. The number ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 2. A diagram of the cell scale metabolic network for APAP metabolism. The
abbreviations are: APAP, acetaminophen; UGTs, UDP-glucuronosyltransferases;
SULTs, sulfotransferase; NQO1, NADPH-quinoreductase; CYPs, cytochrome P450;
APAP-G, acetaminophen glucuronide; APAP-S, acetaminophen sulphate; NAPQI,
N-acetyl-p-benzoquinone imine; GSTs, glutathione S-transferase; GSH, glutathione;
APAP-GSH, acetaminophen glutathione conjugate. Subscript ‘B’ denotes non-spe-
ciﬁc binding to a protein or lipid. Subscript ‘P’ denotes binding to non-speciﬁc
protein (Diaz Ochoa et al., 2012). Blue boxes are non speciﬁcally bound products,
yellow boxes are molecules, white boxes are isozymes, red boxes are protein bound
molecules and green boxes are further metabolic systems not described in this
diagram. (For interpretation of the references to color in this ﬁgure caption, the
reader is referred to the web version of this paper.)
Fig. 3. Pathway Diagram for APAP Metabolism. APAP is metabolised through
3 main pathways, sulphation, glucuronidation and oxidation. CYP oxidation creates
NAPQI, a harmful metabolite which can bind with essential cellular proteins within
the hepatocytes if no GSH is present. Modelled species are APAP (P), NAPQI (N),
PAPS (S), GSH (G) and Drug–Protein Adducts (C).
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doubled over a 4 year period, from 98 deaths in 1997 to 173 deaths
in 2001 (Nourjah et al., 2006). In the UK, 90–155 people died per
year between 2000 and 2008 with additional deaths due to
acetaminophen being taken with other drugs (Hawton et al., 2011).
This ease of availability and lack of awareness of its potential
hazards means that acetaminophen is responsible for 80% of drug-
associated cases of liver injury (Ostapowicz et al., 2002), and drug-
induced liver injury has become the most common cause of acute
liver failure and subsequently transplantation in Western coun-
tries (Lee et al., 2003). Much of our understanding of the meta-
bolism and toxicology of APAP comes from animal models, parti-
cularly rat and mouse. Interestingly there is considerable variation
in toxicity between species (Davis et al., 1974).
APAP is taken orally and is absorbed into the blood stream. It
arrives in the liver via the hepatic portal vein and moves through
the liver mass to the central vein (Fig. 1). In this time, APAP is
absorbed into the hepatocytes where it is metabolised. In the liver,
hepatocyte function is determined by position relative to the
portal vein, with functions differing if a hepatocyte is near the
blood inlet (periportal) or outlet (centrilobular), an affect known
as zonation and is present across all areas of the liver (Allen et al.,
2005). APAP is metabolised in the liver primarily by the sulphation
and glucuronidation pathways (Riches et al., 2009; Mutlib et al.,
2006), while around 5% is metabolised, via oxidation, to form the
toxic metabolite N-acetyl p-benzoquinone imine (NAPQI) (Duan et
al., 2001). A detailed pathway diagram is shown in Fig. 2 and a
simpliﬁed one used as the basis for the mathematical modelling is
shown in Fig. 3. The sulphation pathway involves the conjugation
of APAP with the cosubstrate 3'-phosphoadenosine 5'-phospho-
sulfate or PAPS. This cosubstrate is ﬁnite within the liver cell and at
toxic doses we see PAPS levels fall (Sweeny and Reinke, 1988) and
a saturation of the sulphation pathway, leading to higher meta-
bolism through glucuronidation and oxidation. The cofactors
associated with the glucuronidation pathway have a much higher
capacity than those of the sulphation pathway (Reith et al., 2009)
and we assumed in our modelling that the pathway does not
saturate at clinically relevant, high APAP doses. Via the oxidation
pathway, APAP is catalysed by select enzymes from a ‘superfamily’
of enzymes known as Cytochrome P450 (Patten et al., 1993). The
main enzymes involved in this reaction in human cells are Cyto-
chromes CYP2E1, CYP3A4 and CYP1A2 (Patten et al., 1993; Chen et
al., 1998; Thummel et al., 1993), however, the sub-type and hence
nomenclature of the enzymes varies by species when looking at
animal models. Metabolism through oxidation produces NAPQI, a
chemically reactive and toxic metabolite. NAPQI can be detoxiﬁed
by GSH, an antioxidant which conjugates to NAPQI preventing
binding with essential proteins and thus preventing damage to the
liver. At sufﬁciently high doses, the sulphation cosubstrate, PAPS,
can be exhausted, diverting quantitatively more APAP through the
oxidation pathway, leading to higher amounts of NAPQI beingFig. 1. Structure of the liver (Frevert et al., 2005). Blood ﬂows from the portal ﬁeld
(left) to the central vein. APAP in the blood diffuses into the hepatocytes and is
metabolised.produced. There are marked species differences in the sensitivity
to APAP, e.g. rats are resistant to equivalent doses of APAP com-
pared with humans, and this is due to a much greater capacity for
sulphation and a lowered propensity for oxidation (Vaidyanathan
and Walle, 2002). Oxidation has the effect of depleting GSH levels
in the liver, through binding with NAPQI and hence greater levels
of protein adducts are produced. GSH can also be depleted by
individual factors such as alcoholism (Guerri and Grisolia, 1980)
and anorexia (Kalsi etal., 2011) though this inter-patient variability
is beyond the scope of the mathematical model to be presented in
this paper.
It is broadly recognised that mathematical modelling now plays
a signiﬁcant part in the drug development process. A successful
model provides a cost effective way of understanding and pre-
dicting drug efﬁcacy and toxicology, thus offering a systematic
means of guiding more focused, less exploratory, use of animal
models. Despite acetaminophen being the subject of laboratory
studies for many years, it is only recently that theoretical studies
on the toxicology of paracetamol have been undertaken. One of
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who focused on examining the kinetics of the glucuronidation and
sulphation pathways using a 14 variable ordinary differential
equation ODE) model and ﬁtting to human data, speciﬁcally
excreted products in the plasma. (Ochoa et al.) took a multiscale
approach, combining a detailed cell based APAP metabolism
model, comprised of 34 variables, with a whole body model to
simulate actions in the liver and transport between organs. Both
these models are rich in detail and parameter estimation, but their
complexity prohibits investigation using more advanced mathe-
matical techniques. Multi-compartmental models have also been
tested by Ben-Shachar et al. (2012) who looked to create a model
that would reproduce clinical and experimental data on APAP and
metabolite levels in the plasma and urine. They looked to repro-
duce the data of (Prescott, 1980) examining APAP metabolism in
human patients. Again, this model is complex and so it is difﬁcult
to apply mathematical analysis. Remien et al. (2012) investigate a
simple model for APAP metabolism, utilising a tissue-scale model
to predict biomarker levels, which can be used to estimate over-
dose amount, time elapsed since overdose, and likelihood of
patient survival. In this paper we will present a cell-based model
that describes the major pathways in the system, which is more
detailed then the model proposed by Remien et al. but very much
simpler than that of Reith et al. (2009) and Ochoa et al. This model
will in fact be applicable to a broad range of drugs that are
metabolised in the liver via (1) a non exhaustible pathway (i.e.
glucuronidation), (2) an exhaustible pathway (i.e. sulphation) and
(3) an oxidation pathway that leads to GSH binding and toxic
conjugate formation. The resulting model is amenable to two
forms of analysis. Firstly, to identify which parameters have the
most affect on the predicted outcome through sensitivity analysis
and, secondly, to derive relatively simple formula, using singular
perturbation analysis, for factors such as critical initial dose and
timescales for peak toxic activity. This will enable us to probe the
model to gain great insight in to how individual mechanisms in
the model can affect and inﬂuence these factors. Though the focus
will be on APAP metabolism in humans, the modelling and ana-
lysis is applicable preclinical animal models also.
We seek to create a model that captures the most important
aspects of APAP metabolism and toxicity at the cellular level. We
then analyse the model both numerically and analytically in order
to develop a better understanding of the interactions in the
modelled system. We also wish to identify any data gaps which
can then be pursued experimentally. In the next section we will
derive the model. In Section 3 we present simulations, showing
the metabolic responses to bolus doses of APAP and undertake
parameter sensitivity analysis. In Section 4 we perform a detailed
timescale analysis, to derive formula characterising APAP meta-
bolism. Finally we summarise the key results and discuss future
work in Section 5.Table 1
Model variables and their units.
Variable Interpretation Units
P Paracetamol (APAP) mol/cell
S Sulphate (PAPS) mol/cell
N NAPQI mol/cell
G GSH mol/cell
C Protein adducts mol/cell2. Mathematical modelling
2.1. Model background
We focus on the metabolism of paracetamol within a single
hepatocyte, aiming to capture the main dynamics of APAP meta-
bolism while maintaining enough simplicity that analytical pro-
gress is possible. The full metabolic process is summarised in Fig. 2
and, as stated before, broadly separates into three pathways.
Describing all of the pathways illustrated in Fig. 2 would lead to an
extremely complex model involving 20þ state variables and many
more parameters. Instead, as a ﬁrst approximation, we bundle all
the pathways in the glucuronidation route into a single pathway
and likewise for sulphation and oxidation. The reduced pathwaydiagram used for the model is shown in Fig. 3. We assume for
sulphation and glucuronidation that the ﬁrst reaction down each
pathway is non-, or negligibly, reversible, so that events down-
stream do not directly affect paracetamol metabolism. For the
oxidation pathway, we assume a single generic CYP is involved
which represents the combined actions of CYP2E1, CYP3A4 and
CYP1A2.
2.2. Model description
We use mass action laws to derive a system of ordinary dif-
ferential equations that describe the dynamics over time of the
different pathways illustrated in Fig. 3. The resulting model is the
same as that presented, but not studied, in Williams et al. (2013),
we will nevertheless outline the model derivation. The model
variables are listed in Table 1 and we note they represent quan-
tities per cell.
Our model assumes an initial bolus dose being delivered. The
metabolism depends on the size of the initial dose. At regular
doses the majority of APAP will be metabolised by the sulphation
and glucuronidation pathways (Duan et al., 2001). APAP (P)
undergoes sulphation by reacting with the PAPS enzyme (S) at rate
kSSP, where kS is the rate constant associated with the metabolism
of APAP by PAPS, ultimately forming APAP-S. In humans, PAPS is
exhaustible and so at high doses may, in some situations, see a
saturation of the pathway. We deﬁne the rate constant for the
production of PAPS by the liver as bS and the rate constant for the
natural decay as dS. In contrast, we assume that the enzymes
involved in glucuronidation are not exhaustible and are present at
an approximately constant concentration, hence APAP metabolism
along this pathway is in affect a natural decay at rate kGP .
The remaining APAP is metabolised via the oxidation pathway
creating NAPQI (N). We assume that cytochrome P450 enzymes
are present continuously at an approximately ﬁxed concentration,
so that the oxidative pathway is described as a further “natural
decay” term, k450P. This reaction is assumed reversible at rate kNN .
NAPQI is assumed to be metabolised via one of two pathways.
The ﬁrst is by reaction with the antioxidant GSH (G) at a rate
kGSHNG. At normal doses of APAP we expect to see nearly all of the
NAPQI produced being detoxiﬁed by this pathway. Conjugation
with GSH renders NAPQI harmless and it is excreted from the body
with no ill effects. In our model GSH is assumed to be con-
stitutively produced at a constant rate bG and naturally decays at
rate dGG. In fact, the production and regulation of GSH production
is quite complex, being released from skeletal muscle (Bilinsky et
al., 2015) and regulated as an adaptive mechanism by NRF2
(Klaassen and Reisman, 2010); at the level of detail of the current
model we assume that constant bG is a reasonable starting point
for modelling single doses. The second pathway has NAPQI
creating drug–protein adducts (C) at a rate kPSHN. This binding to
cellular macromolecules can result in cell death if the proteins that
are bound are essential for cell function/viability. We do not con-
sider the downstream events caused by drug-protein adducts and
the variable C represents the total accumulated amount of a toxic
reaction (we therefore hereon refer to C as toxins in that they are
capable of inducing cell death).
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Fig. 3 and including the stated assumptions:
dP
dt
¼ kSSPkGPk450PþkNN; ð1Þ
dS
dt
¼ kSSPþbSdSS; ð2Þ
dN
dt
¼ k450PkNNkGSHNGkPSHN; ð3Þ
dG
dt
¼ kGSHNGþbGdGG; ð4Þ
dC
dt
¼ kPSHN: ð5Þ
We assume in this study that the drug is introduced into cells
as a single bolus dose at t ¼ 0 at a concentration PS. The cells at this
point are assumed to be at pretreatment steady-state level. The
initial conditions for this system are thus
Pð0Þ ¼ PS; Sð0Þ ¼
bS
dS
; Gð0Þ ¼ bG
dG
; N0 ¼ 0; Cð0Þ ¼ 0: ð6Þ
Table 2 lists the model parameters and their estimated values
for the standard simulation. Where possible, we obtained their
values from the literature and any remaining parameters through
repeated simulation, so that the numerical results matched rea-
sonably well with similar simulations from Remien et al. (2012). It
is generally considered that anything more than 4 g taken at once
is considered an overdose, so we use 4 g as our safe dose case
(Craig et al., 2012) (though it is recommended to take no more
than a 1 g dose at 4 h intervals).3. Results
3.1. Simulation
Our aim is to understand the effect of dose on both NAPQI
production and timescales of events in APAP metabolism. We solveTable 2
List of model parameters and values used in standard simulation.
Parameter Value Units Notes
P0 1:32 1013 mol  cell1 See (1)
dG 2 day1 (Ookhtens et al., 1985; Lau-
terburg et al., 1984; Aw et al.,
1986)
bG 1:374 1014 mol  cell1  day1 (Remien et al., 2012)
kGSH 1:6 1018 cell mol1  day1 (Miner and Kissinger, 1979)
kG 2.99 day1 (Reith et al., 2009)
k½nS 2:26 1014 cell mol1  day1 See (2)
b½nS 2:65 1014 mol  cell1  day1 See (2)
d½nS 2 day
1 Equal to dG
k½n450 0.315 day
1 See (3)
k½nN 0.0315 day
1 See (4)
k½nPSH 110 day
1 See (5)
(1) 4 g dosage, standard single dose assuming 80% of dose reaches liver.
(2) Assuming initial PAPS is 10% of standard APAP dose i.e. bSdS ¼
P0
10, and initially
sulphation and glucuronidation are about the same, i.e. kS ¼ kGdSbS i.e. amounts to
47.5% of APAP processing initially.
(3) Equal to kG9:5 i.e. we assumed only 5% of APAP is oxidised initially.
(4) Assumed kN ¼ k45010 i.e. forward reaction is dominant.
(5) Assuming at normal GSH concentration, bGdG , only 1% of NAPQI binds with the
hepatocytes, i.e. kPSH ¼ 0:01kGSHbGdG .
Parameters marked with [*] indicate parameters chosen by us to produce physio-
logically realistic results.the system of Eqs. (1)–(5) using the MATLAB routine ode15s, a
variable order backwards difference method. Unless otherwise
stated, we use the parameter values listed in Table 2.
We ﬁrst examine the single 4 g dose case, i.e. a daily dose in a
single bolus. We expect GSH levels to remain non-negligible to
ensure a safe low-level conjugation of NAPQI. Consequently, pro-
tein adducts will then stay at very low levels. Both of these fea-
tures can be observed from the simulation in Fig. 4 (left column).
It can be seen that neither GSH or Sulphation levels drop to zero,
indicating that all APAP in the system is being dealt with effectively.
We do see a rise in NAPQI, however overall levels are extremely low
relative to our overdose case and therefore do not pose any great
risk. The same can be observed for the protein adducts, which
remain at low levels compared to the overdose case.
For the overdose case of 16 g, a likely outcome is that both GSH
and sulphate levels will become exhausted at some stage of the
metabolism process. This indeed occurs as can be seen in Fig. 4
(right column). Sulphates drop very rapidly to a near zero level
and take a long time to recover; this means that proportionally
more APAP will be conjugated into NAPQI. This leads to a rapid
drop in GSH to negligible levels that are sustained for a period of
about 40 h. This rise in NAPQI and subsequent depletion of GSH
results in a high level of formation of protein adducts in compar-
ison with our safe dose simulation. We note that a 4 increase in
dose leads to an almost 104 increase in accumulated protein
adducts.
Fig. 5 shows the affect of the initial dose on the total amounts
of toxic protein adducts produced, presented as C1=PS, where C1
represents the steady state level i.e. C-C1 as t-1 and the ratio
C1=PS represents the fraction of adduct molecules produced per
APAP molecule. At levels just slightly above a safe dose of 4 g it can
be seen that the amount of protein adducts in the system rises
rapidly. This rapid increase in protein conjugate formation displays
how dangerous overdoses involving APAP are. Small increases in
the dose above what is considered “safe” lead to huge increases in
the protein adducts being produced, which in turn can lead to
extensive damage to the liver. This threshold behaviour is due
entirely to the level of GSH depletion of which leads to the fraction
of protein adducts produced increasing 1000-fold over a 3–5 g
dose (we note that in Remien et al. the lowest doses for patients
receiving treatment is about 5 g). The sensitivity of the model
solutions to parameter change is explored in the next section,
whilst the key parameters governing the threshold dose are
established in the analysis of Section 4. We note that as PS-1, the
sulphation pathway becomes less signiﬁcant and it follows that
C1=PS-k450=ðkGþk450ÞC0:095 as PS-1.
Simulations investigating the effect of smaller regular doses are
shown in Fig. 6, in particular those in the left column represent a
typically prescribed 1 g dose at 4 separate 4 h intervals over a
5 day period. Here, we observe NAPQI progressively building up in
the initial days before settling to a periodic proﬁle. Protein adducts
increase linearly, although total levels still remain negligible.
The right hand side of Fig. 6 plots a higher than recommended
chronic dose case, this time with the patient taking 1.5 g of APAP
every 4 h. This increase in APAP leads to a rapid depletion of GSH
resulting in NAPQI and conjugate levels two orders of magnitude
higher than in the 1 g case. NAPQI and protein adducts both rise
rapidly (after a day) due to the lack of GSH in the system to safely
deal with the NAPQI present. The plots once again show dramatic
increase in toxic effects (represented by an increase in adducts, C)
following a modest overdose.
3.2. Parameter sensitivity analysis
The results in Section 3 demonstrated a notable sensitivity to
dose. In this section we seek to establish the sensitivity of the
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Fig. 4. Plot of the evolution of, from top to bottom, APAP, PAPS, NAPQI, GSH and protein adducts respectively. The units in each graph are mol/cell, noting the two orders of
magnitude difference between the levels in N and C. Here 4 g (left) and 16 g (right) correspond to P0 ¼ 1:32 1013 and P0 ¼ 5:28 1013 mol/cell, respectively.
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146136model solution to changes in parameter values. To do this sys-
tematically we used the Latin Hypercube method implemented
using the “lhsdesign” routine in MATLAB. To produce the resultsthat followed, the routine was set up to run 500 iterations, which
randomly selects parameters between set limits of 3 and 13
their original value. We used, for the sensitivity test, the total
Fig. 5. Plot showing the effect of initial dose (P0) on ﬁnal accumulated toxins
normalised as the ratio C1=PS . The dashed line represents the value of P
n
0 which is
found in Section 4.3.1. The stars represent the location of 4 g and 16 g doses.
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146 137accumulated protein adducts C1 (i.e. CðtÞ as t-1), where we
plotted this against each of the model parameters. We look for
trends in the resulting graphs, indicating higher or lower numbers
of protein adducts in response to a change in parameters. To
conﬁrm our observation we also examined the Sobol indices to
estimate the sensitivity of variance of the model output, C, to the
variance of the parameters (Saltelli, 2008). Deﬁning indices Si (the
ﬁrst order effect) and STi (the total effect index) to be the condi-
tional expectation divided by the unconditional variance and the
total output variation due to a given parameter respectively. Then
STi Si ¼ 0 indicates that a parameter has no affect on the variance
of the model output.
Shown in Fig. 7 are the results of the sensitivity analysis for the
safe dose of 4 g. We observe that most of the graphs do not show
any sort of trend in response to differing parameter values except
that the k450 (oxidation rate constant) graph shows an obvious
upward trend in protein adducts whilst a downward trend is
observed for kG (glucuronidation rate constant). Here, the Sobol
indices are found to be STkG SkGC0:35; STk450 Sk450C0:32 and
STbG SbGC0:2, while all other values are less than 0.05 conﬁrming
the visual analysis of the parameter sensitivity. Interestingly, the
indicated sensitivity to bG is not present in the 16 g case, sug-
gesting that this is likely to be an important parameter when
doses are near to the “critical level”. However, as the Sobol Indices
for bG in the overdose case indicate that it has no signiﬁcant affect
on the model output, we do not feel that any further analysis is
necessary for this parameter. The sensitivity analysis for the
overdose case of 16 g is shown in Fig. 8. Again we see that changes
in the value of k450 and kG produce the most distinct trends in the
model. In the overdose case, STkG SkGC0:16 and
STk450 Sk450C0:06, while all other values are again less than 0.05.
These are the only 2 parameters with a notable affect on the model
outcome in the overdose regime.
This analysis suggests that the key mechanisms that govern
paracetamol metabolism are glucuronidation and oxidation,
where increasing kG reduces toxicity and increasing k450 enhances
it. In the parameter range investigated, PAPS contributes only up to
about 10% of APAP metabolism, whereby sulphation is a secondary
process in humans; we note that the sulphation for rats liesoutside the parameter range investigated. Figs. 9 and 10 show the
dependence of the total toxins produced, C1, on the two most
sensitive parameters k450 and kG, for the safe and overdose cases.
The results were generated from running the simulation to
approximate C1ðt ¼ 50Þ, we found this length of time sufﬁcient to
reach a steady state. From Fig. 9 we see that increased k450 will
lead to more APAP being oxidised instead of being metabolised by
sulphation or glucuronidation. This will cause a rise in the amount
of NAPQI in the system, putting more strain on the GSH pathway.
We anticipate that a higher value for k450 will lead to more protein
adducts being present in the system and therefore increase the
risk of liver damage.
The safe dose response shows a steady increase in conjugate
levels initially, followed by a rapid rise in conjugate levels being
produced with total protein adduct formation increasing by over
one order of magnitude. A less dramatic rise in protein conjugates
is observed for higher k450 values. For our overdose case we see a
much faster rise in the total protein adduct formation in response
to higher k450 levels. We see an increase of approximately three
orders of magnitude in response to higher values of k450. After the
initial rapid increase in total protein adduct formation, higher
values of k450 have a much lower affect on C1. Once GSH is
depleted in our system, all NAPQI that is oxidised will produce
protein adducts, the rate at which these protein adducts can be
formed is then dependent on how quickly NAPQI can be oxidised,
this rate is k450. This suggests that after GSH is depleted fully,
conjugate production will be proportional to k450. The rate of APAP
to NAPQI metabolism can be affected by other factors such as
caffeine consumption (Carter, 1987; Lee et al., 1996) and, for
example, consumption of anti-convulsant drugs (Bray et al., 1992)
which would result in a higher value of k450.
In Fig. 10 we observe, as expected, a decline in toxins produced
as kG increases. As with k450, there is a fairly sharp transition
between high and low toxicity at a certain value of kG. We note
that a 10-fold increase in kG is required in the overdose case ðkG
 18=dayÞ to produce minimal toxic levels in comparison to the
safe doses ðkG  1:5=dayÞ. Furthermore, for kG  0/day there is a
10-fold difference in C1 levels. This is due simply to more APAP
being present for longer in the overdose case. The critical role of
GSH exhaustion is highlighted in Fig. 11, which plots the numeri-
cally predicted minimum value against parameters kG and k450. Of
particular note is how the value of kG and k450 at which the sharp
jumps occur correspond to jumps in Figs. 9 and 10.
Fig. 11 plots the minimum GSH levels in the cell against kG and
k450. As kG increases we see a rise in the minimum GSH level of
2 orders of magnitude. This suggests that if the glucuorindation
rate drops then GSH could fall low enough to allow protein
adducts to form, if for example a person has a genetic or envir-
onmental deﬁciency e.g. co-medication, that reduces the amount
of glucuornidation cofactor it could be dangerous for them to take
paracetamol, even in safe doses. We observe in the overdose case
that only very large values of kG have a non-negligible affect on
minimum GSH levels. An increase in k450 leads to a drop in GSH of
over 3 orders of magnitude in the safe dose case, at the normal
value of k450 ¼ 0:315=day, minimum GSH levels remain high in the
cell. However, an increase in k450 leads to lower GSH levels which
could lead to the formation of protein adducts. Therefore,
increased k450 can potentially lead to liver damage via protein
adduct formation even in safe dose cases.
3.3. Cellular dose variation
The structure of the liver lobule means that cells closer to the
portal vein are likely to receive more of the drug. As a con-
sequence, there will be a distribution of drug dosage between cells
in the liver. Some cells which receive higher doses are more likely
Fig. 6. Plots showing evolution of pathways over time in response to a 1 g per dose (left) and 1.5 g per dose (right) chronic APAP regimen.
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146138to be damaged than others. Furthermore, differences in micro-
environment due to proximity to blood vessels and oxygen gra-
dients could also affect drug metabolism. The effects of the micro-environment will be subject to a future publication, and here we
investigate how the spread of drug dosing effects the probability of
cell death given a dose.
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Fig. 7. Final accumulated toxic levels from a 4 g (‘safe') dose against each of the parameters for 1000 iterations of randomly selected values between the limits of 1/3x and 3x
the nominal value listed in Table 2.
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Fig. 8. Final accumulated toxic levels from a 16 g overdose against each of the parameters for 1000 iterations of randomly selected values between the limits of 1/3x and 3x
the nominal value listed in Table 2.
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Fig. 9. Total protein adduct formation against k450 for the safe (4 g, dashed) and
overdose (16 g, solid) cases. The dotted line indicates the standard value corre-
sponding to data in Table 2.
Fig. 10. Total protein adduct formation vs. kG for the safe (4 g, dashed) and over-
dose (16 g, solid) cases. The dotted line indicates the standard value of kG found in
Table 2.
Fig. 11. Plot showing minimum GSH levels in the hepatocytes against kG (left) and k450 (r
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146140In Fig. 12, we assume that a dose of paracetamol is log-normally
distributed between the hepatocytes in the liver. We assumed that
a lethal dose for cells (pL)is 5 times the daily safe dose (Remien et
al., 2012) and we plotted the probability p4pL, given a mean dose
log ðpsÞ and variance σ2, against mean dose. We observe that
higher standard deviations lead to a less sharp proﬁle. It is
expected that 70% total cell death will lead to the death of the
patient (Remien et al., 2012), in our simulations we see that this
occurs from  7 1013 mol=cell (approx. 5 times the standard
dose) to  9 1013 mol/cell (approx. 7 times the standard
dose). Interestingly, we also see that greater variation between
hepatocytes leads to more deaths at lower doses, but less death at
higher doses. This suggests that variation is a positive property for
the population on average, for survival against a very large, single
dose. However, this does not necessarily mean it is a positive
property for the individual.4. Timescale analysis
In the previous section we were able to get some insight into
how certain parameters effect the predicted toxicological outcome.
In this section we will employ singular perturbation theory to get a
much better analytical understanding of APAP metabolism
according to the model. Close examination of Fig. 4 reveals the
existence of distinct timescales, starting with a rapid decline in
PAPS and GSH followed by longer timescales for recovery. To apply
this theory we ﬁrst non-dimensionalise the system of Eqs. (1)–(5).
Using the data values in Table 2, we express the new parameters in
terms of a single small parameter ϵ (i.e. ϵ⪡1), which will be
exploited in the analysis. We will summarise the main results here,
and we refer the reader to the supplemental material for full
details.
4.1. Non-dimensionalisation
To aid the analysis we rescale our variables in order to elim-
inate units, which allows comparison of variables and parameters
in terms of their magnitude, so that the dominant and negligible
mechanisms can be systematically identiﬁed. Since glucuronida-
tion is the dominant metabolism route for APAP, we rescale timeight). The dotted vertical lines indicate the original parameters values from Table 2.
Table 3
Table of dimensionless parameters, their values and the assumed value relative to
the reference small parameter ϵ.
Parameter Deﬁnition Value Order in terms of ϵ
k^450 k450=kG 0.105 ϵ
k^N kN=kG 0.0105 Oðϵ2Þ
α^S kSbS=dSkG 1 Oð1Þ
ϕ^S P0dS=bS 10 Oð1ϵÞ
δ^S dS=kG 0.668 Oð1Þ
k^PSH kPSH=kG 36.8 Oð1ϵÞ
α^G kGSHbG=dGkG 3680 Oð 1ϵ3Þ
ϕ^G P0dG=bG 19.3 Oð1ϵÞ
δ^G dG=kG 0.668 Oð1Þ
Fig. 12. Plot showing the fraction of cell death in response to an increasing initial
paracetamol dose, normally distributed amongst cells.
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146 141with parameter kG; using the value in Table 2, the dimensionless
time t^ ¼ 1 thus represents about 8 h. We rescale PAPS and GSH
with their untreated levels and rescale APAP, NAPQI and protein
adducts to a reference value P0 which represents the liver cell level
of a 4 g dose i.e. P0 ¼ 1:32 1013 mol/cell. The rescalings are thus
t ¼ 1
kG
t^ ; P ¼ P0p^; S¼
bS
dS
s^; N¼ P0n^; G¼
bG
dG
g^ ; C ¼ P0c^:
and we note the standard dose concentration P0 corresponds to
p^ ¼ 1. The dimensionless system of equations is then
dp^
dt^
¼ α^nS s^p^ p^ϵp^þϵ2k^
n
Nn^; ð7Þ
ds^
dt^
¼  α^
n
Sϕ^
n
S s^p^
ϵ
þ δ^nS ð1 s^Þ; ð8Þ
dn^
dt^
¼ ϵp^ϵ2k^nNn^
k^
n
PSH
ϵ
n^ α^
n
G
ϵ3
n^g^ ; ð9Þ
dg^
dt^
¼  α^
n
Gϕ^
n
G
ϵ4
n^g^þ δ^nGð1 g^Þ; ð10Þ
dc^
dt^
¼ k^
n
PSH
ϵ
n^; ð11Þ
where the rescaled parameters are listed in Table 3. The third
column of Table 3 lists the value of the parameter, and for the
purpose of the analysis we will rewrite them in terms of the small
parameter ϵ¼ k450=kGC0:1 guided by magnitudes indicated in the
4th column; thus starred values in Eqs. (7)–(11) are deﬁned as
k^N ¼ ϵ2k^
n
N and α^S ¼ α^nS . These dimensionless variables are subject
to the initial conditions
p^ð0Þ ¼ PS; s^ð0Þ ¼ 1; n^ð0Þ ¼ 0; g^ð0Þ ¼ 1; c^ð0Þ ¼ 0;
recalling that PS ¼ 1 represents the 4 g dose case. Henceforth, we
will drop the hats and the n's for clarity. In Section 4.2 we provide
an overview of the main mathematical results and we then give
biological interpretations in Section 4.3.4.2. Application of singular perturbation theory
The system (7)–(11) will be analysed in the limit ϵ-0. Using
singular perturbation theory we can perform this analysis sys-
tematically and formally reduce the full system to a sequence of
timescales in which the system reduces to a simpler solvable one
in each timescale. This will enable us to identify when a particular
process is important and determine an approximation to key
quantities such as critical dose in terms of the model parameters.
Full details of the analysis is given in the supplementary material
and we present only the “highlights” below. A summary of this
analysis and the important timescales and events is provided in
Section 4.3. We note that toxic levels of protein adducts will be
c¼ Oðϵ2Þ as shown in Fig. 5.
4.2.1. t¼Oðϵ3Þ
On introduction of the APAP bolus there is a rapid adjustment
over t ¼Oðϵ3Þ, the ﬁrst 30 seconds or so, in which NAPQI is pro-
duced at very low levels. Denoting variables in this timescale with
a superscript n, we write
t ¼ ϵ3τn; p¼ pn; s¼ sn; n¼ ϵ4nn; g ¼ gn; c¼ ϵ6cn:
These rescalings are then substituted into our dimensionless
equations (7)–(11), subject to pn ¼ PS; sn ¼ 1; gn ¼ 1;nn ¼ 0 and cn
¼ 0 at tn ¼ 0. In each timescale we seek solutions of the form:
pðτnÞ ¼ pn0ðτnÞþϵpn1ðτnÞþϵ2pn2ðτnÞþ⋯
and likewise for the other variables. Substituting these expansions
into our equations we obtain to leading order pn  PS; sn  1 and
gn  1 (correction terms can be found in our supplementary
material) and
nn  PS
αG
ð1eαGτn Þ;
cn  kPSHPSðαGτ
nþeαGτn1Þ
α2G
:
In this short initial timescale, APAP, PAPS and GSH remain
relatively unchanged and NAPQI equilibrates to a negligible Oðϵ4Þ
level. As tn-1, NAPQI settles to n ϵ4 PS=αG
 
and
c ϵ6 kPSHPS τn=αG
 
. We note here that as τn-1;n ϵ4PS =αG,
this represents the amount of NAPQI formed if PAPS and GSH
remain at their pretreatment levels. There is no change at leading
order of p; s and g, however the correction terms become Oð1Þ at
τn ¼ Oðϵ2Þ i.e. at t ¼OðϵÞ.
4.2.2. t¼ OðϵÞ
It is on this timescale at which sulphation is most prominent.
We introduce t ¼ ϵτ and the relevant rescalings are
p¼ p; s¼ s; n¼ ϵ4n; g ¼ g ; c¼ ϵ4c:
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146142Substituting the expansions above, p  p0þϵp1 etc. into (7)–
(11) and solving leads to
p  PSþϵ
1
ϕS
ðeαSϕSPS τ1ÞPS τ
 
;
s  eαSϕSPS τ ;
g  1þϵðϕGPS τÞ;
n  PS
αG
;
c  kPSHPS
αG
τ :
In this timescale, we see that sulphate levels drop rapidly
whilst APAP is relatively steady. Biologically this is due to the
conjugation of APAP and PAPS, leading to declining PAPS levels in
the cell. The parameters used suggest that the pretreated PAPS
concentration is OðϵPSÞ so, at best, sulphates are only able to
metabolise an OðϵÞ fraction of the drug. There is also an increase in
protein adducts, although they are still only present in very low
amounts. We note as τ-1; p  PSϵ ϕ1S þPS τ
 
, where ϵ=ϕS
represents the amount of APAP being metabolised by the sulpha-
tion pathway. There is a transition timescale t ¼ ϵ η1ðϵÞþOðϵÞ,
where η1 ¼ lnð1=ϵÞ=αSϕSPS, in which sulphate reaches a minimum
constant level, namely s ϵδS=αSϕSPS; sulphation makes no fur-
ther contribution to APAP metabolism at leading order. The
expansion breaks down when τ ¼Oð1=ϵÞ, corresponding to
t ¼Oð1Þ, when APAP concentration starts to signiﬁcantly drop.
4.2.3. t¼Oð1Þ
In this timescale, we have two separate divergent cases. One in
which we have sufﬁcient amounts of GSH in the system to con-
jugate NAPQI, the other is characterised by a rapid drop in GSH
and potential toxin build up. The critical dose at which the two
cases diverge is
PnS ¼
δδG=ðδG1ÞG
ϕG
; ð12Þ
such that, PSoPnS can be classiﬁed as “safe” and PS4PnS can be
considered a potential overdose. We note here that we have
assumed that δGa1, we will omit details for the coincidental case
of δG ¼ 1 (i.e. δG ¼ kG in dimensional terms).
In both cases, we adopt the following rescaling:
t ¼ ~τ ; p¼ ~p; s¼ ϵ~s; n¼ ϵ4 ~n; g ¼ ~g ; c¼ ϵ3 ~c:
Expanding these variables in the usual way, and solving the
resulting system yields
~p  PS e ~τ ϵ e ~τ ð
δS
ϕS
PS ~τÞ
δS
ϕS
 
; ð13Þ
~s  δSe
~τ
αSϕSPS
; ð14Þ
~n  PS e
 ~τ
αG
ϕGPS
δG1
eδG ~τ e ~τ þ1
 ¼ PS e τ
αGΨ ðτÞ
; ð15Þ
~g  ϕGPS
δG1
ðeδG ~τe ~τ Þþ1¼Ψ ðτÞ; ð16Þ
~c  kPSH
Z ~τ
0
~nð ~τÞ d ~τ : ð17Þ
Here, APAP is metabolised such that p PS eτ (due to glu-
curonidation at leading order) and that PAPS is recovering, noting
that s¼ OðϵÞ and therefore is not contributing to APAP metabolism
at leading order. We also note that ~c is unsolvable in this timescale,but we can deduce behaviour as ~τ- ~τn (see below), as explained in
the supplementary material.
The divergence depends on the function
Ψ ð ~τÞ ¼ 1þ ϕGPS
δG1
ðeδG ~τ e ~τ Þ; 8 ~τ40
whereby if Ψ ð ~τÞ40, 8 ~τ40, then ~n and ~g remain positive and
Oð1Þ, this is our safe dose case. If at ~τ ¼ ~τn, such that Ψ ð ~τnÞ ¼ 0,
then ~n-1 in ﬁnite time ~τ- ~τn whilst ~g-0. The divergence
condition ðPS ¼ PnS Þ is determined by assuming that Ψ ð ~τnÞ ¼ 0 is a
turning point at ~τ ¼ ~τn , i.e. solving Ψ ð ~τn Þ ¼ 0 and Ψ 0ð ~τn Þ ¼ 0
simultaneously leading to tn ¼ lnδ=ðδ1Þ. We note that the safe
and overdose cases can be connected smoothly by analysis in the
region of PS ¼ PnSþϵθ, where θCOð1Þ. The results are omitted as
they are not of biological signiﬁcance other than it reveals that the
jump region observed in Fig. 5 is of OðϵÞ ¼ Oðk450=kGÞ in size.
In the overdose case, when PS4P
n
S , breakdown occurs when
t  μ1ðϵÞ, where μ1ðϵÞ is deﬁned such that Ψ ðμ1ð0ÞÞ ¼ 0; and ~g ¼
OðϵÞ and ~n ¼Oð1=ϵÞ. Here, μ1ðϵÞ is the time at which hepatocytes
no longer have an effective means of dealing with NAPQI. It is
straightforward to show that μ1ðϵÞ is a decreasing function of PS
and dg, i.e. more drug and less glutathione reduces the time
interval, as expected. We further note that given Ψ ðμ1Þ ¼ 0 and
Ψ 0ðμ1Þo0 we can show that ϕGPS eμ14δG; this result is utilised
in Section 4.2.5. In the overdose case, breakdown occurs when
t  ~τn ¼ μ1ðϵÞ, where Ψ μ1ð0Þ
 ¼ 0 and Ψ ð ~τÞ ¼OðϵÞ, so that ~g ¼Oð
ϵÞ and ~n ¼ Oð1=ϵÞ, this is discussed in Section 4.2.5.
4.2.4. Safe dose case ðPSoPnSÞ
Here, the drug decays exponentially (predominantly by glu-
curonidation) and ~g ¼Oð1Þ throughout, i.e. GSH is able to handle
the NAPQI being produced. Meanwhile sulphate cofactors are
recovering but only at very low levels. Protein adducts attain their
maximum level i.e. Oðϵ3Þ, namely
c1  ϵ3kPSHPSαG
Z 1
0
eτ
Ψ ðτÞ dτ
There is a further timescale at t ¼ lnð1=ϵÞþOð1Þ in which the
sulphation factors, now Oð1Þ, continue to recover, and return to
pre-treatment state.
4.2.5. t¼ μ1ðϵÞþOð1Þ (overdose)
GSH and NAPQI continue to drop and rise, respectively, over a
series of intermediate timescales until the current one describing
the time period at which GSH is at its minimum level. We rescale
our variables as follows:
t ¼ μ1þ τ ; p¼ p; s¼ ϵs; n¼ ϵ2 n; g ¼ ϵ2 g ; c¼ ϵc:
We then expand our variables as before, substitute them into
(7)–(11) and solve to ﬁnd
p  PS eðμ1  τ Þ;
s  δSe
μ1
αSϕSPS
;
n ϕGPS e
μ1 τδG
kPSHϕG
;
g  δGkPSH
αGðϕGPS eμ1 τ δGÞ
;
c  PS eμ1 ð1e τ Þ
δG
ϕG
τ
In this timescale APAP levels continue to drop while sulphates
remain steady. Protein adducts approach their maximum level
while NAPQI production begins to slow and GSH levels begin to
rise as APAP levels decline. The solutions in this timescale break-
down as τ-μ2ðϵÞ , with μ2ð0Þ ¼ lnðϕGPS=δGÞμ1ð0Þ, where g ¼O
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146 143ð1=ϵÞ and n ¼ OðϵÞ. After this timescale, NAPQI levels begin to
decline. As τ-μ2 , c attains its maximum value to leading order,
i.e. c1  ϵðPS eμ1 ð1eμ2 Þμ2δG=ϕGÞ. We can show that the
amount of protein adducts increases with PS (i.e. higher initial
dose) and ϕG (less GSH present) as would be expected.
4.2.6. t¼ μ1ðϵÞþμ2ðϵÞþOð1Þ(overdose)
This timescale follows a series of intermediate timescales in
which GSH rapidly recovers and NAPQI diminishes. Here, the
rescalings are
t ¼ μ1þμ2þτo; p¼ po; s¼ ϵso; n¼ ϵ4no; g¼ go; c¼ ϵco
and proceeding as before
po  PS eμ1 μ2 τ
o
so  δSe
μ1þμ2 þτo
αSϕSPS
no  PS e
μ1μ2 τo
αG
ϕGPS e
μ1 μ2
δG1
ðeδGτo e τo Þþ1
 
go ϕGPS e
μ1 μ2
δG1
ðeδGτo e τo Þþ1
co  PS eμ1 ð1eμ2 Þ
δG
kG
μ2
Here we see that APAP levels continue to drop exponentially,
allowing PAPS levels to rise exponentially. GSH levels are now Oð1Þ
and will soon recover to its pretreated level, whilst the tiny
amounts of NAPQI that remain rapidly decrease. We now have
GSH returning to pretreated levels as NAPQI diminishes.Fig. 13. Plots of APAP, Sulphates, Drug–Protein Adducts and GSH against dimensionless
graph when ϵ¼ 0:1052. The horizontal dashed line shows our analytical estimate for C
discussed in section 4.3.4, 4.3.5 and 4.3.6.After this, the only timescale of signiﬁcance is
τo ¼ lnð1=ϵÞþOð1Þ, whereby p-OðϵÞ and s-Oð1Þ, i.e. their pre-
treated levels.
4.2.7. Comparison with numerics
Fig. 13 shows the evolution of the dimensionless APAP, PAPS
and GSH concentrations against dimensionless time in an over-
dose case (left). As expected, the agreement improves as ϵ
decreases (right).4.3. Timescale analysis summary
Here we summarise the important events and timescales from
the previous section, expressing the key dimensionless quantities
in their dimensional form.
4.3.1. Critical paracetamol concentration
In Section 4.2.3, where t ¼ Oð1Þ we observe a divergence
between our safe and overdose cases. This divergence occurs at a
critical concentration
PnS 
dG
kG
 kG=ðdG kGÞbG
kG
; ð18Þ
where PnS ¼ 1:47 1013 mol=cell using the data available in
Table 2. We note 4 g translates to a concentration of 1:32 1013
mol=cell and our divergence happens at a point 11% above this
dose. This highlights the relatively low tolerance the liver has in
response to large bolus doses of paracetamol.time in an overdose case, the left hand graph when ϵ¼ 0:105 and the right hand
1 , the vertical dashed lines show the estimates for GSH collapse and recovery as
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–1461444.3.2. Exhaustion of sulphate
Our analysis shows that sulphate is exhausted in the inter-
mediate timescale between 4.2.2 and 4.2.3. The approximate
timescale for exhaustion of sulphate is
t  k450
kGkSPS
lnðkG=k450Þ;
which using the data is t  12 min for a 4 g dose. After this point
the pathway saturates and we a greater proportion of APAP being
metabolised into NAPQI, impacting GSH levels. We note that the
estimate is only logarithmically accurate and will not be as precise
as those in Sections 4.3.1, 4.3.4, and 4.3.5 are; nevertheless it
makes explicit how much faster PAPS is exhausted in response to
an increased drug dose.
4.3.3. Sulphate recovery
In both safe and overdose cases, we see sulphate recover at
t ¼ lnð1=ϵÞ, in dimensional parameters this is
t  1
kG
ln
kS PS kG
dS k450
 
:
Using the data this equates to about 40 h after ingestion for a
4 g dose; though we note, like that of Section 4.3.2, this estimate is
only logarithmically accurate. Sulphate recovery is a long term
process and the liver takes a long time to recover from a high
paracetamol dose. In the case where a person uses paracetamol
chronically to deal with pain then this long recovery time could
impact how well the liver can deal with multiple doses. We note,
as expected, that the recovery time is extended with dose, but in a
sublinear fashion.
4.3.4. GSH depletion
In our overdose case, when PS4P
n
S we observe a collapse in
GSH levels at t  μ1 (Section 4.2.3). Where μ1 satisﬁes the implicit
equation
1þ kGdGPS
bGðdGkGÞ
edGμ1 ekGμ1
 
¼ 0:
This equation cannot be solved directly to ﬁnd μ1 but given
values of the parameters, the equation can be solved using the
Newton–Raphson method. Using the data in Table 2 gives μ1 
0:046 for the overdose case, which using dimensionless para-
meters is μ1  0:138 which is in good agreement with the numeric
values shown in Fig. 13. We then show that mathematically we can
improve our estimate by reducing the size of ϵ. Similarly, we ﬁnd
t  μ2  2:358 in the overdose case, again providing good agree-
ment with the numeric values shown in Fig. 13. In terms of
dimensional parameters this gives us μ2  0:79, which is discussed
further in Section 4.3.5.
4.3.5. GSH recovery
Again looking at the case where PS4P
n
S , the time for GSH
recovery is given by
t  1
kG
ln
kGPS
bG
 
which is approximately 8.9 h for a 4 g dose and 20 h for a 16 g
dose. People regularly taking high doses of APAP can cause
damage by not allowing time for GSH recovery and subsequently
protein adduct formation could be high. Again, the plot in Fig. 13
shows how this estimate of GSH recovery is accurate for our model
and how smaller values of ϵ (i.e. a decreasing k450=kG ratio)
increase the accuracy of our estimate.4.3.6. Total protein conjugate formation, C1
The total concentration of drug–protein adducts in the over-
dose case, PS4P
n
S , is
C1 
k450PS ekgμ1
kG
bGk450
k2G
1þkGμ2
 
We note that the accumulated drug–protein adducts total is
unaffected (to leading order) by parameters associated with PAPS.
Moreover, we can show that C1 increases with an increasing
initial APAP dose and CYP reaction rate, and decreases in response
to an increasing GSH production rate and glucuronidation reac-
tion, as expected. Fig. 13 shows that this offers a fair prediction of
maximum drug–protein adduct levels. We note that no para-
meters associated with sulphation have an affect on the ﬁnal
accumulation of protein conjugate formation and suggest that the
sulphation pathway is unlikely to be a suitable target for an
effective new treatment against the toxicological effects of an
APAP overdose. However, we should note that even though sul-
phates are “exhausted” by time t  lnðkG=k450Þ=kGPS it is still
removing APAP at around the same rate as the oxidative pathway
between timescales 4–10 (see supplemental material).5. Discussion
In this paper, we have derived a cell scale mathematical model
which describes the metabolism of APAP in hepatocytes. In order
to obtain insights into this system using analytical methods, we
simpliﬁed the full metabolic pathway to one that still maintains
the three major pathways.
The simulations demonstrated that the model captures the
expected dynamics of metabolism and, in particular, the distin-
guishing dynamics between the safe and overdose cases. We
observe the expected drops in both sulphate and GSH levels in the
safe dose case and our overdose simulations have both pathways
dropping rapidly to very low levels, which is what we expect from
clinical observation. The results show that a 4 dose of APAP can
lead to a 100–10,000 increase in the amount of protein adducts
being formed.
Our sensitivity analysis has enabled us to identify the most
sensitive parameters in our model, we can use these to guide the
research of biologists which will then provide further insight and
help us to reﬁne our model. The analysis in Section 3.2 showed
that the key parameters are kG (the rate constant for glucur-
onidation) and k450 (the rate of oxidation); the other parameters
have secondary effects on the dynamics and, in particular, the
sulphation pathway is less inﬂuential than glucuronidation and
oxidation. There is ongoing work by the authors examining
adaptive responses to chronic dosing. For example, if certain
pathways become up-regulated in response to mild liver stress
caused by APAP, then these sensitive parameters may be one of the
contributing factors.
It can be seen that system operates over a number of distinct
timescales. At t ¼OðϵÞ  45 min we see sulphate levels begin to
decline in response to the APAP present. As time progresses, we
observe that sulphates begin to decline, and by t ¼Oð1Þ  8 h we
see that sulphates have become exhausted as they drop by an
order of magnitude (i.e. S¼ OðϵÞ). At this stage in our analysis, we
see a critical divergence between the safe dose and overdose cases
at an initial paracetamol dose of 4.54 g (using data from Table 2).
We also are able to identify timescales for exhaustion and recovery
of GSH and sulphates (details of which are available in the sup-
plementary material). Of course there can be considerable indivi-
dual variability that can affect the critical dose level. The sensi-
tivity analysis has enabled us to deduce that changes in kG and k450
D. Reddyhoff et al. / Journal of Theoretical Biology 386 (2015) 132–146 145have the largest impact on the dynamics of the system. Further to
this, the asymptotic analysis of Section 4 has allowed us to express
key quantities (critical concentrations and timescales) in terms of
relatively simple formula (Section 4.3), so the effect of varying
parameters can be explicitly observed. Such methods have broad
application and are somewhat underused in the study of mathe-
matical models in pharmacology.
Our parameter selection is good but there are gaps in the cur-
rent literature that highlight a need for more data on the meta-
bolism of APAP in humans. While literature is available which has
allowed us to begin parameterisation, further experimental work
would beneﬁt the robustness of the model greatly. The parameter
values for glucuronidation and oxidation pathways are obtainable
from the literature, whilst that of sulphation is less well char-
acterised. Though the analysis in this paper suggests that acet-
aminophen metabolism via the sulphation pathway is secondary
in humans, it appears to be important in rats (Reith et al., 2009),
which are much more resistant to APAP at human toxic levels.
Consequently the critical concentration expression, Eq. (18), will
be completely different for rats; we expect that the model is sui-
tably generic to describe acetaminophen metabolism in other
species with little modiﬁcation. However, to fully understand the
contrast between rat and human models, for example, more data
on metabolism via. sulphation and subsequent model repar-
amaterisation for the different species is essential.
Through numerical, sensitivity and asymptotic analysis we
have improved our understanding of how the different pathways
behave. We have highlighted key parameters that our system is
sensitive to and also found how the pathways interact with each
other, and how this affects the production of protein adducts and
the potential for toxicity. This work will provide a foundation on
which to build by working directly with scientiﬁc researchers and
provides us with new areas to research and expand upon using the
existing model.
This research is part of a larger project funded by the National
Centre for the Replacement, Reﬁnement and Reduction of Animals
in Research (NC3R's) which aims to improve in vitro testing and
reduce the animal testing in science (Krewski et al., 2010). From
the initial results and insights, this model is an encouraging ﬁrst
step towards the long-term goal of combining modelling and
experimental approaches to mitigate the use of animal testing in
toxicological studies, for example, testing hypotheses which would
normally be tested in animal models. Its simplicity and analytical
tractability means that we can draw conclusions on key para-
meters that can then be found from in vitro data.Competing interests
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